DeMasi R - Search Results

1

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

Melby T, Sista P, DeMasi R, Kirkland T, Roberts N, Salgo M, Heilek-Snyder G, Cammack N, Matthews TJ, Greenberg ML. Melby T, et al. Among authors: demasi r. AIDS Res Hum Retroviruses. 2006 May;22(5):375-85. doi: 10.1089/aid.2006.22.375. AIDS Res Hum Retroviruses. 2006. PMID: 16706613 Clinical Trial.

2

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.

Melby T, Demasi R, Cammack N, Miralles GD, Greenberg ML. Melby T, et al. Among authors: demasi r. AIDS Res Hum Retroviruses. 2007 Nov;23(11):1366-73. doi: 10.1089/aid.2006.0277. AIDS Res Hum Retroviruses. 2007. PMID: 18184079

3

Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.

Melby TE, Despirito M, Demasi RA, Heilek G, Thommes JA, Greenberg ML, Graham N. Melby TE, et al. AIDS. 2007 Nov 30;21(18):2537-9. doi: 10.1097/QAD.0b013e3282f12362. AIDS. 2007. PMID: 18025893 Clinical Trial.

4

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Matthews T, et al. Among authors: demasi r. Nat Rev Drug Discov. 2004 Mar;3(3):215-25. doi: 10.1038/nrd1331. Nat Rev Drug Discov. 2004. PMID: 15031735 Review.

5

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.

Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML. Sista PR, et al. Among authors: demasi r. AIDS. 2004 Sep 3;18(13):1787-94. doi: 10.1097/00002030-200409030-00007. AIDS. 2004. PMID: 15316339 Clinical Trial.

6

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg ML, Graham N. Melby T, et al. Among authors: demasi r. J Infect Dis. 2006 Jul 15;194(2):238-46. doi: 10.1086/504693. Epub 2006 Jun 2. J Infect Dis. 2006. PMID: 16779731 Clinical Trial.

7

Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.

Su C, Melby T, DeMasi R, Ravindran P, Heilek-Snyder G. Su C, et al. Among authors: demasi r. J Clin Virol. 2006 Aug;36(4):249-57. doi: 10.1016/j.jcv.2006.03.007. Epub 2006 Jun 9. J Clin Virol. 2006. PMID: 16765082 Clinical Trial.

8

Adherence to enfuvirtide and its impact on treatment efficacy.

Rockstroh J, Dejesus E, Donatacci L, Wat C, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Guimaraes D, Wilkinson M, Thommes J, Rowell L, Demasi R, Salgo M. Rockstroh J, et al. Among authors: demasi r. AIDS Res Hum Retroviruses. 2008 Feb;24(2):141-8. doi: 10.1089/aid.2006.0231. AIDS Res Hum Retroviruses. 2008. PMID: 18240965 Clinical Trial.

9

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H, Zhang Y, Spence R, Greenberg ML, Demasi RA, Miralles GD; T1249-102 Study Group. Lalezari JP, et al. Among authors: demasi ra. J Infect Dis. 2005 Apr 1;191(7):1155-63. doi: 10.1086/427993. Epub 2005 Feb 22. J Infect Dis. 2005. PMID: 15747252 Clinical Trial.

10

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. Eron JJ, et al. Among authors: demasi r. J Infect Dis. 2004 Mar 15;189(6):1075-83. doi: 10.1086/381707. Epub 2004 Mar 2. J Infect Dis. 2004. PMID: 14999611 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters